This annual report evaluates the array of differing state medical cannabis programs across the country from a perspective often overlooked in policy debates - the patients - and provides policy makers with model legislation and regulations. With dozens of states already seeing legislative and regulatory proposals in 2016, this groundbreaking report will provide state lawmakers with timely tools they need to improve their medical cannabis programs to truly meet the needs of the patients they are meant to serve.

This report comes at a perfect time to inform improvements to existing medical marijuana programs and guide legislators who are creating or expanding laws and programs. “Too often, patients are denied life-saving treatments solely because they are using medical cannabis,” said California Assemblymember Marc Levine, champion of the Medical Cannabis Organ Transplant Act (AB 258), “It is imperative for state lawmakers to take advantage of vital resources like ASA’s report to improve their state programs.”

The report uses a point system to grade each medical marijuana law on:

1. Patients' rights and protection from discrimination
2. Access to medicine
3. Ease of navigation
4. Functionality
5. Product safety protocols

The report found that while many states have important elements helpful to patients, no state has yet established an ideal, comprehensive program.

Letter-grades for all 23 state laws and Washington, D.C.: Alaska (D-), Arizona (B-), California (B+), Colorado (B), Connecticut (C+), Delaware (C), Hawaii (B), Georgia (F), Illinois (B+), Iowa (F), Louisiana (F), Maine (B-), Maryland (B), Massachusetts (B), Michigan (D+), Minnesota (C), Montana (D-), Nevada (B), New Hampshire (C), New Jersey (C), New Mexico (B+), New York (C), Oregon (B), Rhode Island (C-), Vermont (D+), Washington (B), and the District of Columbia (C).